{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.9","upperLimit":"27.8","value":"24.0"},{"groupId":"OG001","lowerLimit":"12.7","upperLimit":"19.4","value":"15.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"232"},{"groupId":"OG001","value":"210"}],"units":"Participants"}],"description":"The duration of response is defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression. The end of response should coincide with the date of progression or death from any cause used for the progression-free survival endpoint. The time of the initial response is defined as the latest of the dates contributing towards the first response of Partial response or Complete response.\n\nMedian values of the duration of response, along with two-sided 95% CI in each treatment group were computed using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Osimertinib (AZD9291) 80 mg in combination with pemetrexed (500 mg/m2) plus either cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21-day cycles for 4 cycles, followed by Osimertinib (AZD9291) 80 mg QD with Pemetrexed maintenance (500 mg/m2) Q3W","id":"OG000","title":"Randomized: AZD9291 + Chemo"},{"description":"Osimertinib (AZD9291) 80mg QD.","id":"OG001","title":"Randomized: AZD9291"}],"paramType":"MEDIAN","populationDescription":"Participants from the Full Analysis Set, which includes all randomized participants, that had a response.","reportingStatus":"POSTED","timeFrame":"Up to approximately 33 months after the first patient is randomized.","title":"Duration of Response (DoR) (Randomized Component)","type":"SECONDARY","unitOfMeasure":"Months"}